Nuclear matrix protein [NMP 22] as a diagnostic tool in urinary bladder cancer

ABSTRACT

To evaluate the role of urinary nuclear matrix protein NMP22 in urinary bladder cancer diagnosis. From August 2003 to January 2007, 373 patients, were enrolled in this study in Al Noor Specialist Hospital K.S.A and Urology Department in Benha Faculty of Medicine, patients were complaining of hematuria, LUTS, and bladder mass suspected On U/S examination, after clinical evaluation including complete history, general and local examination especially D.R.E, 50 ml of midstream morning urine samples was taken from all patients and examined for complete urine analysis and for detection of urine level of NMP 22 assay, cystoscopy, and TUR resection was done for all the patients and comparative analysis was done for the results of the cystoscopy, histopathology and NMP22 assay results. The results of the present study revealed that there was decreased overall sensitivity [28.2%] and specificity was [75%] ofNMP 22 in diagnosing transitional cell carcinoma of the bladder in comparison with confirmed cystoscopic positive results [98.8%] but the specificity and sensitivity increases in large invasive tumors to be [56.7%], and specificity [75%]. NMP22 could be considered a diagnostic or screening tool only in high grade transitional cell carcinoma, invasive or large advancing tumor, but NMP22 could not replace cystoscopy as the gold standard for cancer bladder diagnosis